Table 1.

Cancer Cases, Relative Risks, and Cumulative Incidence of Cancer After Baseline Diagnoses (95% CI^*)

				Cancer Incidence
Cytometric Measure	n	No. Cancers	RR (95% CI)	3 yr	5 yr
4N
>6%	52	24	12 (6.2, 22)	53 (37, 69)	57 (41, 74)
>15%†	13	6	10 (4.1, 27)	39	39
6–15%†	39	18	12 (6.2, 24)	56 (39, 75)	62
≤6%	255	18		4.7 (2.6, 8.7)	6.5 (3.6, 11.6)
Aneuploid
Yes	45	16	5.9 (3.1, 11)	43 (27, 62)	43 (27, 62)
No	262	26		7.7 (4.8, 12)	10 (6.6, 16)
Aneuploid (ploidy > 2.7N)
Yes	34	15	9.5 (4.9, 18)	64	64
No	273	27		7.4 (4.6, 12)	10 (6.3, 15)
Aneuploid (>2.7N)/4N > 6
+/+	23	12	23 (10, 50)	75	75
+/−	11	3	7.9 (2.3, 28)	46	46
−/+	29	12	10 (4.7, 22)	41 (24, 63)	48
−/−	244	15		3.4 (1.6, 7.0)	5.2 (2.6, 10)
Either positive	63	27	13 (6.7, 25)	51 (37, 67)	55 (40, 71)
S Phase
>5.5%	164	30	2.3 (1.2, 4.4)	17 (12, 25)	21 (15, 30)
≤5.5%	143	12		6.6 (3.3, 13)	6.6 (3.3, 13)
S Phase
>9%	44	9	2.0 (.94, 4.1)	21 (11, 40)	28 (14, 51)
≤9%	263	33		11 (7.3, 16)	13 (8.6, 18)

RR = relative risk.

^*95% CI provided at times when more than five patients at risk for esophageal adenocarcinoma are still followed.

^†Reference group is ≤6%.